

ORIGINAL ARTICLE

Pulmonary function tests and respiratory symptoms among smokers in the city of mashhad (north east of Iran)

M.H. Boskabady^{a,*}, M. Mahmoodinia^a, M. Boskabady^a, G.R. Heydari^b

^a Department of Physiology and Pharmaceutical Research Centre, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran

^b Tobacco Prevention and Control Research Centre, Iran

Received 5 December 2010; accepted 1 March 2011

Available online 12 June 2011

KEYWORDS

Prevalence of smoking;
smoking duration;
smoking amount;
pulmonary function tests;
respiratory symptoms

Abstract The prevalence of smoking was studied using a questionnaire. Pulmonary function tests and respiratory symptoms were evaluated in 176 smokers. The total studied population with family and co-workers were 13289. The number of smokers among studied population was 11.7%. The rate of smoking among male subjects was 17.2% and in female 2.5%. All values of PFTs in smokers were significantly lower ($p < 0.001$) and respiratory symptoms higher than in non smokers ($p < 0.05$ for cough and $p < 0.001$ for wheeze and tightness). There were significant negative correlations between smoking duration and rate with values of PFT ($p < 0.05$ - $p < 0.001$). In this study the prevalence of smoking in population of Mashhad city was shown. The prevalence of smoking was higher among male than females. Smoking leads to increased respiratory symptoms and reduction of PFTs values.

© 2010 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights reserved.

PALAVRAS-CHAVE

Prevalência do acto de fumar;
Duração do acto de fumar;
Quantidade do acto de fumar;
Testes de função pulmonar;
Sintomas respiratórios

Testes de função pulmonar e sintomas respiratórios em fumadores iranianos

Resumo A prevalência do acto de fumar foi estudada através de um questionário. Os testes de função pulmonar e sintomas respiratórios foram avaliados em 176 fumadores. O total da população estudada com família e colaboradores foi de 13289. O número de fumadores entre a população estudada foi de 11,7%. A taxa do acto de fumar entre os homens foi de 17,2% e de 2,5% entre as mulheres. Todos os valores de TFP nos fumadores foram significativamente inferiores ($p < 0.001$) e os sintomas respiratórios foram superiores em relação aos não fumadores ($p < 0,05$ para tosse e $p < 0,001$ para pieira e aperto torácico). Registaram-se correlações negativas significativas entre a duração do acto de fumar e a taxa com valores de TFP ($p < 0,05$ - $p < 0,001$). Neste estudo, foi apresentada a prevalência do acto de fumar na população da cidade de Mashhad.

* Corresponding author.

E-mail addresses: boskabadyhm@mums.ac.ir, mhboskabady@hotmail.com (M.H. Boskabady).

A prevalência do acto de fumar foi maior entre os homens do que entre as mulheres. Fumar leva a um aumento de sintomas respiratórios e à redução dos valores de TFP.

© 2010 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os direitos reservados.

Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity throughout the world. Many people suffer from this disease for years and die prematurely from it or its complications. COPD is currently the fourth leading cause of death in the world¹ and further increases in its prevalence and mortality can be predicted in the coming decades.²

Cigarette smoking is by far the most important risk factor for COPD and the most important way that tobacco contributes to the risk of COPD.³ Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, greater annual rate of decline in FEV₁ and a greater COPD mortality rate than non-smokers.⁴ These differences between cigarette smokers and non-smokers are in direct proportion to the quantity of smoking. Smoking leads to rapid decline in pulmonary function tests (PFTs) especially those indicating diameter of the airways such as forced expiratory flow in one second (FEV₁).⁵ Even in teenagers who have smoked only a few years, maximum expiratory flow-volume curves demonstrate decreases in flow rates at small lung volumes,⁶ yet another expression of small airway obstruction. Until now, the only well-documented acute effect of smoking on the airways was the decrease of airway conductance demonstrated by Nadel and Comroe.⁷ The obstruction to airflow that develops in 15 to 20% of heavy smokers is thought to be due to abnormalities in airways less than 2 mm internal diameter.⁸ Previous studies from several laboratories have shown that this airway obstruction is associated with a chronic inflammatory process in the membranous and respiratory bronchioles.^{9,10} It is believed that the airway constriction in COPD and decline in PFTs is not reversible.

Therefore, in the present study the prevalence of smoking in the city of Mashhad and the effect of quantity and duration of smoking on PFTs and the respiratory symptoms were examined.

Methods

Study area and population

The data of directly interviewed subjects (1435 subjects including 999 male and 436 female) and their relatives (totally 13289 subjects) aged 10 year and over (Table 1) regarding prevalence of smoking were collected from 21 randomly selected areas in the city of Mashhad using clustering sampling method and a list of different areas of the city. The city of Mashhad has moderate industry and heavy traffic. Mashhad is a holy city located in the north east of Iran with a population of two-million people, many of whom are immigrants from all over Iran.

Protocol

A Farsi questionnaire was used to assess the prevalence of smoking among population of the city of Mashhad and the respiratory symptoms. The questionnaire included two different parts: 1) part (a) questions on regular smoking, amount and duration of smoking and 2) part (b) respiratory symptoms (wheezing, tightness, cough and sputum). The interviewed subjects were asked the questions from both parts but relatives of interviewed subjects were only asked questions from part (a). In addition, 150 non smokers of similar age and sex distribution were interviewed and their respiratory symptoms were evaluated as a control group. The studied (interviewed subjects) were interviewed face to face by two trained final medical students. The questionnaire was validated in our two previous studies.^{11,12} The questionnaire on respiratory symptoms was designed in accordance with several previous questionnaires of similar studies by expert groups,^{13–15} (Table 2).

Pulmonary function tests of smokers and control groups were measured using a spirometer with a pneumotachograph sensor (Model ST90, Fukuda, Sangyo Co., Ltd. Japan). Prior to pulmonary function testing, the required manoeuvre was demonstrated by the operator, and subjects were encouraged and supervised throughout the test performance. Pulmonary function testing was performed using the acceptability standards outlined by the American Thoracic Society (ATS) with subjects in a standing position and wearing nose clips.¹⁶ All tests were carried out between 1000 and 1700 hours. Pulmonary function tests were performed three times in each subject with an acceptable technique. Subjects were educated prior to PFT measurements regarding the PFT performance. PFT measurements were carried out three times in each subject and there were small variation among three measurements. The highest level for forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), peak expiratory flow (PEF), maximal mid expiratory flow (MMEF) and maximal expiratory flow at 75%, 50%, and 25% of the FVC (MEF₇₅, MEF₅₀, and MEF₂₅ respectively) were taken independently from the three curves. The study was

Table 1 The age distribution among studied population.

Age (years)	Male	Female	Total
10-19	14	15	29
20-29	175	53	228
30-39	285	114	399
40-49	267	132	399
50-59	162	73	235
60-69	68	42	110
> 70	28	7	35
Total	999	436	1435

Table 2 The criteria for asthma severity score.

Symptom	Frequency	Score
Wheezing	None	0
	During mild exercise (walking)	1
	During heavy exercise	2
	At rest	3
Cough	None	0
	During mild exercise (walking)	1
	During heavy exercise	2
	At rest	3
Tightness	None	0
	During mild exercise (walking)	1
	During heavy exercise	2
	At rest	3
Sputum	None	0
	Small volumes of non purulent sputum	1
	Large volumes of non purulent sputum	2
	Purulent sputum	3
Total score		12

approved by the ethical comity of Mashhad University of Medical Sciences.

Data analysis

Based on the prevalence of smoking in Iran,^{17,18} using the PPS sampling method, it was calculated that a minimum of 1300 subjects (900 male and 400 female) would be needed to detect a 5% difference with an (error of 1% and a power of 95%. Therefore, 1435 subjects including 999 male and 436 female were interviewed. The data of PFT values and age were expressed as mean \pm SD and data of smoking and respiratory symptoms as percentage of each group having the correspond symptom. Differences in the data of symptoms between smokers and control group were tested by Chi-Squared analysis on 2X2 contingency tables. The data of PFT values between smokers and control group were compared using unpaired t test. The relationships between PFT values and respiratory symptoms with duration and quantity of smoking were performed using regression analysis. A two-sided p value of 0.05 was the criterion for statistical significance. All analyses were performed with SPSS software (version 11.5, SPSS Inc. USA).

Results

Prevalence of smoking

The prevalence of smoking among all studied individuals including relatives of interviewed subjects was 11.7% (1554 out of 13289 subjects), (Table 3).

Smoking was more prevalent among population of Golshar area and less prevalent in Ahmad Abad area (a poor and rich populated area of Mashhad city respectively). Generally smoking was more prevalent in poorer populated area of the

Table 3 Prevalence of smoking among population of different region and total studied subjects in the city of Mashhad.

Region	Studied Subjects	Smokers	Prevalence (%)
Faramarz Abasi Bulv.	275	33	12%
Azad Shahr	985	105	10.6%
Sajad Bulv	621	62	10%
Vakil Abad Bulv	995	110	11%
Pirozi Bulv, Reza Shahr	748	77	10.3%
Vahdat Bulv	617	78	12.6%
Saydi	598	79	13.2%
Shahid Mofateh Bulv	621	77	12.4%
Kalat Road	427	50	11.7%
Resalat Bulv	646	70	10.8%
Gol Shahr	603	88	14.6%
Tabarsi Bulv	702	91	13%
Najafi Shahrak, Hor Sq.	910	110	12%
Farhang Bulv	623	70	11.2%
Andishah Bulv	624	74	11.8%
Ahmad Abad, Ghaem	621	55	8.9%
Behшти St.	623	74	11.8%
Imam Reza St.	900	115	12.8%
Ghasem Abad	600	70	11.7%
Eshrat Abad Cross	260	30	11.5%
Northern Shahrokh	290	36	12.4%
Total	13289	1554	11.7%

Stu: studied subjects, S.: Smokers, %: prevalence of smoking (percentage).

city (Table 3). The prevalence of smoking was much lower in female (2.5%) compared to male (17.2) subjects.

Respiratory symptoms

The most and the least prevalent respiratory symptoms among smokers were tightness and cough respectively. About one third (34%) of smokers reported tightness and only 17% had cough symptom. However, the prevalence of all respiratory symptoms among smokers was higher compared to those in control group which was statistically significant except sputum ($p < 0.05$ to $p < 0.001$), (Table 4).

The severity of most respiratory symptoms was also greater in smokers compared to non smoker subjects which

Table 4 Comparison of respiratory symptoms severity between smokers and non-smokers.

Respiratory symptoms	Smokers	Non-smokers	Statis. dif.
Wheezing	0.48 \pm 0.88	0.16 \pm 0.59	$p < 0.05$
Tightness	0.62 \pm 0.90	0.31 \pm 0.90	$p < 0.05$
Cough	0.28 \pm 0.67	0.18 \pm 0.75	NS
Sputum	0.25 \pm 0.53	0.26 \pm 0.81	NS

Values were presents as mean \pm SD, NS: non significant differences. Differences in the data of symptoms between smokers and control group were tested by Chi-Squared analysis on 2X2 contingency tables.




Figure 1 Comparison of prevalence of respiratory symptoms (percentage of subjects of each group having the corresponding symptoms) between smokers (lighter filled bars) and non-smokers (darker filled bars), (for smokers and non smokers $n = 176$ and 150 respectively). NS: non significant differences, *: $p < 0.05$, ***: $p < 0.001$.

was statistically significant for wheezing and breathlessness ($p < 0.05$ for both cases), (Fig. 1).

Pulmonary function test

Although some values of pulmonary function tests in smokers were around normal range of 80% predicted values (MFEF, MEF₅₀ and MEF₂₅), all values of PFT among smokers were significantly lower than those of non smokers ($p < 0.001$ for all cases), (Fig. 2).




Figure 2 Comparison of pulmonary function tests (Mean \pm SD) between smokers (lighter filled bars) and non-smokers (darker filled bars), (for smokers and non smokers $n = 176$ and 150 respectively). FVC: forced vital capacity, FEV₁: forced expiratory volume in one second, MMEF: maximal mid expiratory flow, PEF: peak expiratory flow, MEF₇₅, MEF₅₀, and MEF₂₅: maximal expiratory flow at 75%, 50%, and 25% of the FVC, respectively. ***: $p < 0.001$. The data of PFT values between smokers and control group were compared using unpaired t test.

Table 5 Relationship between respiratory symptoms in smokers with smoking duration (year) and amount (pack/year).

Respiratory symptoms	Duration		Amount	
	R	P	R	P
Wheezing	0.158	$p < 0.05$	0.087	NS
Tightness	0.146	NS	0.008	NS
Cough	0.044	NS	0.027	NS
Sputum	0.141	NS	0.036	NS

NS: non significant differences. The relationships between respiratory symptoms with duration and quantity of smoking were performed using regression analysis.

Table 6 Relationship between pulmonary function tests (PFT) of smokers with smoking duration (year) and amount (pack/year).

PFT Values	Duration		Amount	
	R	P	R	P
FVC	-0.224	$p < 0.01$	-0.127	NS
FEV ₁	-0.282	$p < 0.001$	-0.163	$p < 0.05$
MMEF	-0.306	$p < 0.001$	-0.137	NS
PEF	-0.241	$p < 0.005$	-0.121	NS
MEF ₇₅	-0.247	$P < 0.005$	-0.170	$p < 0.05$
MEF ₅₀	-0.305	$P < 0.001$	-0.144	NS
MEF ₂₅	-0.236	$P < 0.005$	-0.072	NS

NS: non significant differences.

Relationship between smoking duration and amount with pulmonary function tests and respiratory symptoms of smokers

The relationship between respiratory symptoms for only wheezing with duration of smoking (year) was statistically significant ($p < 0.05$), (Table 5). There were significant negative relationships between duration of smoking with all PFT values ($p < 0.01$ to $p < 0.001$) and amount of smoking (pack/year) with only FEV₁ and MEF₇₅ ($p < 0.05$ for both cases), (Table 6).

Discussion

In the present study which was performed in a relatively large population sample, the prevalence of smoking in the city of Mashhad (north east Iran) was studied. The respiratory symptoms and PFT values of smokers in comparison to non-smokers were also evaluated. The results showed that 11.7% of the population of the city are regular smokers. The results also indicated that prevalence of smoking is higher among population of poor area of the city.

The prevalence of smoking was much lower in female (2.5%) compared to male (17.2) subjects.

The results of study of Ahmadi et al. showed higher prevalence of smoking in the city of Shiraz (18.7%).¹⁷ The sample population of their study was smaller compared to the present study which might be the reason for the differences in the prevalence of smoking between two

studies. The other reason for the differences in prevalence of smoking between Shiraz and Mashhad city could be the differences in the culture of the populations of the two cities. In another study, Ahmadi et al. showed a smoking prevalence of 25% among nursing students in Iran.¹⁸ Turčić et al., also showed a higher smoking prevalence among male (27.2%) compared to female subjects (12.6) among old population of Zagreb.¹⁹ However, the difference in the prevalence of smoking between male and females in this part of Europe is much lower than that of the population of Iran.

The results also showed increased respiratory symptoms and reduction of all values of pulmonary function tests in smokers compared to those of non-smoker subjects. Although the mean values of PFTs in smokers were around the normal range, all PFT values were significantly lower in smokers than non smokers. The increased respiratory symptoms and reduction of PFT values in smokers showed the effect of smoking on respiratory system. However, those PFT values indicating the diameter of smaller airways (MMEF, MEF₅₀ and MEF₂₅) were less affected in smokers. The relationship between quantity of smoking and respiratory symptoms was not significant but the correlation between only wheezing and duration of smoking was significant. However, there were significant and negative correlations between all PFT values with duration and some PFT values (FEV₁ and FEF₇₅) with quantity of smoking. The relations between respiratory symptoms and PFT values with quantity and duration of smoking are further confirmation of profound effect of smoking on respiratory system.

The results of the study of Turčić et al. also showed higher prevalence of respiratory symptoms including cough and breathlessness among smokers compared to non smokers¹⁹ which support the results of the present study. Rigalado-Pineda et al. also showed a higher prevalence of respiratory symptoms among smokers in Mexico population.²⁰ However, the weak correlations between respiratory symptoms and both quantity and duration of smoking seen in the present study is perhaps due to the subjective characteristics of the symptoms. In addition, the respiratory symptoms occurred after profound disorder of respiratory system which usually happened due to long time and high quantity of smoking. As it is clear in Fig. 1, all respiratory symptoms in smokers are higher than in non smokers which are statistically significant except sputum. The reason that there is no significant difference in sputum prevalence and severity of cough and sputum between smokers and non-smokers is perhaps because of the relatively short duration of smoking among population of the present study, especially in the younger age groups and in females which constitute more than two third of total smokers.

Several previous studies also showed reduction of different values of PFTs among smoker compared to normal subjects.^{21–29} The result of the present study showed that the reduction in PEF and MEF₇₅ among smoker subjects was significantly more than other values of PFTs. These results may indicate that in smoker subjects, medium and large airways are more affected by smoking than other airways. The results of our study were supported by previous studies indicating reduction of mainly PEF, MMEF and MEF₇₅ in smokers.^{30–33} However, a study showed that small airways are more affected by smoking.²² In addition, various

other studies showed reduction of other PFT values including FEV₁,^{19,20,34–36} MMEF and MEF₅₀,³² MEF₂₅ and MEF₅₀.¹⁹ The differences in reduction of different PFT values in different studies could be due to the type of cigarettes smoked, the age of studied population or duration and/or quantity of smoking. The results of our previous study in a smaller population and in mild smokers also showed similar results i.e. small airways are more affected by smoking.³⁷ Most of the above studies also showed reduction in FVC value.

The results of the present study also showed significant negative correlations between all PFTs values with amount and duration of smoking. However, correlation between PFTs values and durations of smoking was greater than the correlation between PFTs values and quantity of smoking. These results showed that duration of smoking has more profound effect on airways than quantity of smoking. The studies of Jaakkola et al.³⁵ Sherrill et al.³⁸ and Verschakelen et al.³⁹ also showed correlations between smoking and reduction of most PFTs values, supporting the results of the present study. In addition, Burrows et al. also showed quantities relationship between cigarette smoking and reduction in PFTs values.⁵ Our previous study also showed greater correlation between PFTs values and duration of smoking compared to the correlation between PFTs values and quantity of smoking.³⁷

Conclusion

In conclusion, the results of the present study showed an 11.7% prevalence of smoking among population of the city of Mashhad. The prevalence of smoking was significantly higher among males than females. The results also demonstrated the profound effect of smoking on PFTs specially those indicating large airways. There were also increased respiratory symptoms among smokers.

Conflict of interests

Authors declare that they don't have any conflict of interests.

Acknowledgements

This study was financially supported by the Tobacco Prevention and Control Research Centre and also supported by the Research Department of Mashhad University of Medical Sciences.

References

1. World Health Organization. *World health report*. Geneva: World Health Organization; 2000.
2. Murray CJL, Lopez AD. Evidence-based health policy-lessons from the global burden of disease study. *Science*. 1996;274:740–3.
3. Gillyooly M, Lamb D. Microscopic emphysema in relation to age and smoking habit. *Thorax*. 1993;48:491–5.
4. Lebowitz MD, Burrows B. Quantitative relationships between cigarette smoking and chronic productive cough. *Int J Epidemiol*. 1977;16:107–13.
5. Jaakkola MS, Ernst P, Jaakkola JJ, L N'gan'ga W, Becklake MR. Effect of cigarette smoking on evolution of ventilatory lung

- function in young adults: an eight year longitudinal study. *Thorax*. 1991;46:907–13.
6. Gold DR, Wang X, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. *N Engl J Med*. 1996;335:931–7.
 7. Rees PJ, Chowienczyk PJ, Clark TJ. Immediate response to cigarette smoke. *Thorax*. 1982;37:417–22.
 8. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med*. 2004;350:2645–53.
 9. Berend N, Wright JL, Thurlbeck MW, Marlin GE, Woolcock AJ. Small airways disease: reproducibility of measurements and correlation with lung function. *Chest*. 1981;79:263–8.
 10. Wright JL, Lawson LM, Pare PD, Kennedy S, Wiggs B, Hogg JC. The detection of small airways disease. *Am Rev Respir Dis*. 1984;129:989–94.
 11. Boskabady MH, Fasihfar M. Correlation between symptom score, reversibility of pulmonary function tests and treatment response in asthma. *Ir J Allergy Asthma Immunol*. 2003;2:61–7.
 12. Boskabady MH, Azdaki N. Effect of inhalation technique on the bronchodilatory response to the salbutamol Inhaler in asthmatic patients. *Turkish Respir J*. 2005;6:10–4.
 13. Bellia V, Pistelli F, Giannini D, Scichilone N, Catalano F, Spatafora M, et al. Questionnaires, spirometry and PEF monitoring in epidemiological studies on elderly respiratory patients. *Eur Respir J*. 2003;21 Suppl. 40:21s–7s.
 14. National Institutes of Health. Global strategy for asthma management and prevention: NHBLI workshop report. Bethesda, MD, January, Publication No. 02-3659. 2002.
 15. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. *Am J Respir Crit Care Med*. 1999;160:893–8.
 16. American Thoracic Society. Standardization of spirometry: 1994 Update. Official Statement of American Thoracic Society. *Am J Respir Crit Care Med*. 1995;152:1107–36.
 17. Ahmadi J, Khalili H, Jooybar R, Namazi N, Mohammadagaei P. Prevalence of smoking in Iran. *Psychol Rep*. 2001;89:339–41.
 18. Ahmadi G, Mahrlooy N, Alishahi M. Substance abuse: Prevalence in a sample of nursing students. *J Clin Nurs*. 2004;13:60–4.
 19. Turčić N, Zuskin E, Mustajbegović J, Smolej-Narancić N, Ivanković D. Respiratory symptom, disease and pulmonary ventilation capacity in person in the third stage of life. *Lijec Vjesn*. 2002;124:247–54.
 20. Rigalado-Pineda J, Gomez-Gomez A, Ramirez-Acosta J, Vazquez-Garcia JC. Effect of tobacco smoking, respiratory symptoms and asthma on spirometry among adults attending a check up clinic in Mexico. *Salud Publica Mex*. 2005;47:327–34.
 21. Prokhorov AV, Emmons KM, Pallonen UE, Tsoh JY. Respiratory response to cigarette smoking among adolescent smokers: a pilot study. *Prev Med*. 1996;25:633–40.
 22. Lange P, Groth S, Nyboe J, Morten J, Appleyard M, Jensen G, et al. Effects of smoking and changes in smoking habits on the decline of FEV1. *Eur Respir J*. 1989;2:811–6.
 23. Bosken CH, Wiggs BR, Pare PD, Hogg JC. Small airway dimensions in smokers with obstruction to airflow. *Am Rev Respir Dis*. 1990;142:563–70.
 24. Eidelman DH, Ghezzi H, Kim WD, Hyatt RE, Cosio MG. Pressure-volume curves in smokers, comparison with alpha-1-antitrypsin deficiency. *Am Rev Respir Dis*. 1989;139:1452–8.
 25. Aparici M, Fernandez Gonzalez AL, Alegria E. Respiratory function tests, differences between smokers and non smokers: Effects of withdrawal. *Rev Clin Esp*. 1993;192:169–72.
 26. Nemery B, Moavero NE, Brasseur L, Stanescu DC. Changes in lung function after smoking cessation: an assessment from a cross-sectional survey. *Am Rev Respir Dis*. 1982;125:122–4.
 27. Lubinski W, Targowski T, Frank-Piskorska A. Evaluation of tobacco smoking on pulmonary function in young men. *Pneumonol Alergol Pol*. 2000;68:226–31.
 28. Aydin O, Dursun AB, Kurt B, Aloglu V, Alpar S, Ucar N, et al. Correlation of Functional and Radiological Findings of Lung in Asymptomatic Smokers. *Turkish Respir J*. 2008;9:15–9.
 29. Welty C, Weiss ST, Tager IB, Munoz A, Becker C, Speizer FE, et al. The relationship of airways responsiveness to cold air, cigarette smoking, and atopy to respiratory symptoms and pulmonary function in adults. *Am Rev Respir Dis*. 1984;130:198–203.
 30. Geijer RM, Sachs AP, Hoes AW, Salome PL, Lammers JW, Verheij TJ. Prevalence of undetected persistent airflow obstruction in male smokers 40-65 years old. *Fam Pract*. 2005;22:485–9.
 31. Khan A, Shabbir K, Ansari JK, Zia N. Comparison of forced expiratory volume in one second (FEV1) among asymptomatic smokers and non-smokers. *J Pak Med Assoc*. 2010;60:209–13.
 32. Bajentri AL, Veeranna N, Dixit PD, Kulkarni SB. Effect of 2-5 years of tobacco smoking on ventilatory function tests. *J Indian Med Assoc*. 2003;101:96–7.
 33. Gregg I, Nunn AJ. Peak expiratory flow in symptomless elderly smokers. *Br Med J*. 1989;298:1071–2.
 34. Padmavathy KM. Comparative study of pulmonary function variable in relation to type of smoking. *Indian J Physiol Pharmacol*. 2008;52:93–196.
 35. Jaakkola MS, Ernst P, Jaakkola JJ, Becklake MR. Ventilatory lung function in young cigarette smokers: a study of susceptibility. *Eur Respir J*. 1991;4:643–50.
 36. Omory H, Nonomi Y, Morimoto Y. Effect of smoking on FEV decline in a cross-sectional and longitudinal study of a large cohort of Japanese males. *Respirology*. 2005;10:464–9.
 37. Boskabady MH, Dehghani H, Esmaeilizadah M. Pulmonary function tests and their reversibility in smokers. *Tanafoos*. 2003;2:23–30.
 38. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Longitudinal methods for describing the relationship between pulmonary function, respiratory symptoms and smoking in elderly subjects, The Tucson Study. *Eur Respir J*. 1993;6:325–7.
 39. Varschakelen JA, Scheinbaum K, Bogaert J, Demedts M, Iacquet LL, Baert AL. Expiratory CT in cigarette smokers: correlation between areas of decreased lung attenuation, pulmonary function tests and smoking history. *Eur Radiol*. 1998;8:1391–9.